Evidence map›Paper›PMID 28777506›Full record

ArticleJournal of the International AIDS Society2017

When patients fail UNAIDS' last 90 - the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a

Niklaus Daniel Labhardt, Isaac Ringera, Thabo Ishmael Lejone, Molisana Cheleboi, Sarah Wagner, Josephine Muhairwe, Thomas Klimkait

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Niklaus Daniel LabhardtClinical Research Unit, Department Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Isaac RingeraSolidarMed, Country-Programme Lesotho, Swiss Organization for Health in Africa, Maseru, Lesotho.
Thabo Ishmael LejoneSolidarMed, Country-Programme Lesotho, Swiss Organization for Health in Africa, Maseru, Lesotho.
Molisana CheleboiLaboratory Services, Butha-Buthe District Hospital, Butha-Buthe, Lesotho.
Sarah WagnerMolecular Virology, Department of Biomedicine - Petersplatz, University of Basel, Basel, Switzerland.
Josephine MuhairweSolidarMed, Country-Programme Lesotho, Swiss Organization for Health in Africa, Maseru, Lesotho.
Thomas KlimkaitMolecular Virology, Department of Biomedicine - Petersplatz, University of Basel, Basel, Switzerland.

Funding

Swiss Foundation for Excellence and Talent in Biomedical Research
6 · The paper itself

Abstract

introductionHIV-infected individuals on first-line antiretroviral therapy (ART) in resource-limited settings who do not achieve the last "90" (viral suppression) enter a complex care cascade: enhanced adherence counselling (EAC), repetition of viral load (VL) and switch to second-line ART aiming to achieve resuppression. This study describes the "failure cascade" in patients in Lesotho.

methodsPatients aged ≥16 years on first-line ART at 10 facilities in rural Lesotho received a first-time VL in June 2014. Those with VL ≥80 copies/mL were included in a cohort. The care cascade was assessed at four points: attendance of EAC, result of follow-up VL after EAC, switch to second-line in case of sustained unsuppressed VL and outcome 18 months after the initial unsuppressed VL. Multivariate logistic regression was used to assess predictors of being retained in care with viral resuppression at follow-up.

resultsOut of 1563 patients who underwent first-time VL, 138 (8.8%) had unsuppressed VL in June 2014. Out of these, 124 (90%) attended EAC and 116 (84%) had follow-up VL (4 died, 2 transferred out, 11 lost, 5 switched to second-line before follow-up VL). Among the 116 with follow-up VL, 36 (31%) achieved resuppression. Out of the 80 with sustained unsuppressed VL, 58 were switched to second-line, the remaining continued first line. At 18 months' follow-up in December 2015, out of the initially 138 with unsuppressed VL, 56 (41%) were in care and virally suppressed, 37 (27%) were in care with unsuppressed VL and the remaining 45 (33%) were lost, dead, transferred to another clinic or without documented VL. Achieving viral resuppression after EAC (adjusted odds ratio (aOR): 5.02; 95% confidence interval: 1.14-22.09;

conclusionsIn this study in rural Lesotho, outcomes along the "failure cascade" were poor. To improve outcomes in this vulnerable patient group who fails the last "90", programmes need to focus on timely EAC and switch to second line for cases with continuous viremia despite EAC.

Indexed as

Treatment FailureAdultAnti-HIV AgentsCohort StudiesCounselingFemaleHealth ResourcesHIV InfectionsHumansLesothoMaleMiddle AgedProspective StudiesRural PopulationViral LoadAnti-HIV Agents90-90-90antiretroviral therapycascadeHIVresistancesecond linetreatment failureviral load

Identifiers

PMID28777506
PMCPMC5577637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.